Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Bile Duct Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Non-Small Cell Lung Cancer Metastatic

Endometrial Neoplasms

Gallbladder Cancer Unresectable

Cholangiocarcinoma

Carcinoma, Hepatocellular

Urinary Bladder Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lung Neoplasms, Small Cell Lung Carcinoma

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

Cholangiocarcinoma

Oropharyngeal Neoplasms

Carcinoma, Transitional Cell

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Liver Neoplasms

Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma, Hepatocellular

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

Carcinoma, Hepatocellular

Small Cell Lung Carcinoma

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

Small Cell Lung Carcinoma

Lung Neoplasms, Small Cell Lung Carcinoma

Bile Duct Neoplasms, Cholangiocarcinoma

Limited Stage Small Cell Lung Cancer

Breast Neoplasms

Carcinoma, Hepatocellular, Cholangiocarcinoma

Carcinoma, Hepatocellular

Liver Neoplasms

Pancreatic Neoplasms

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Hemangiosarcoma, Liposarcoma, Osteosarcoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Glioblastoma

Gastric Adenocarcinoma

Non-Muscle Invasive Bladder Neoplasms

Carcinoma, Hepatocellular

Biliary Tract Neoplasms

Clinical Trials

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Ablatio

DIAMOND

REVIVE

STAGGER

RAINBO

GCND

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

CompARE

RESOLVE

I-SPY

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

SPRINT 2

Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

IOSPHERE

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

MIGRANT

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab

MOZART

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

DUMELEP

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

DURVALUNG

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

TIGOS-LS

DTP

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

ADAPT-BLADDER

DOSa

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

STERIMGLI

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

ENHANCE

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer